FDA-cleared profile

HealthOST

NanoxAI Ltd. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Qualitative and quantitative spine analysis from CT images to support clinician evaluation of musculoskeletal spinal disease, including vertebral labeling, vertebral height-loss measurement, and mean vertebral Hounsfield-unit measurement in patients aged 50 and over.

Clinical role
Post-acquisition DICOM CT validation and analysis in parallel with standard image storage and clinician availability, with automated vertebral labeling, segmentation, height and HU measurements, configurable flags, and clinician review.
Images and patients
CT/CTA · Spine, including T1-L4 vertebrae and T11-L4 trabecular bone regions
Key limitation
Keep in mind: Use is limited to patients aged 50 and over, FBP-reconstructed CT, and the required vertebral coverage. Height-loss and bone-attenuation display thresholds are configurable from predefined lists. Axial analysis is a backup when sagittal data are unavailable, and the device is not intended as a standalone diagnostic tool.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Qualitative and quantitative spine analysis from CT images to support clinician evaluation of musculoskeletal spinal disease, including vertebral labeling, vertebral height-loss measurement, and mean vertebral Hounsfield-unit measurement in patients aged 50 and over.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Spine, including T1-L4 vertebrae and T11-L4 trabecular bone regions Input: DICOM CT scans of patients aged 50 and over undergoing any clinical indication, with at least four vertebrae in the T1-L4 portion for height-loss analysis and the T11-L4 portion for bone attenuation; FBP-reconstructed images only. Sagittal scans are intended, with axial scans as backup when sagittal scans are unavailable.
  • Who uses it?Intended users: Clinicians, including radiologists and physicians in emergency medicine, specialty care, urgent care, and general practice.
  • What does the software produce?Output: For each analyzed vertebra, a vertebral name, percentage height loss based on anterior/middle/posterior measurements, an indication when height loss exceeds a configurable threshold defaulting to >20%, mean trabecular-bone HU for T11-L4 with a configurable low-attenuation indication, and flags for significant height deviation from neighboring vertebrae.
  • What is its most important limitation?Key limitation: Use is limited to patients aged 50 and over, FBP-reconstructed CT, and the required vertebral coverage. Height-loss and bone-attenuation display thresholds are configurable from predefined lists. Axial analysis is a backup when sagittal data are unavailable, and the device is not intended as a standalone diagnostic tool.

Clinical takeaway. Clinical role: Qualitative and quantitative spine analysis from CT images to support clinician evaluation of musculoskeletal spinal disease, including vertebral labeling, vertebral height-loss measurement, and mean vertebral Hounsfield-unit measurement in patients aged 50 and over.

Evidence takeaway. Evidence from the reviewed source record: FDA stand-alone retrospective testing used 150 anonymized CT cases containing 1,425 vertebrae from two healthcare institutions with multiple US and OUS clinical sites; ground truth was determined by three US board-certified radiologists. Overall vertebral-naming agreement was 91.49% (95% CI [89.91%, 92.89%]); height-loss 95% limits of agreement were [-7.98, 7.36], with 91.86% of differences within the ground-truth readers' limits; agreement for classifying height loss above or below 20% was 91.28%; bone-attenuation 95% limits of agreement were [-20.83, 18.29], with 96.06% of differences within ground-truth readers' limits. These are agreement and limits-of-agreement endpoints, not sensitivity or specificity.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Qualitative and quantitative spine analysis from CT images to support clinician evaluation of musculoskeletal spinal disease, including vertebral labeling, vertebral height-loss measurement, and mean vertebral Hounsfield-unit measurement in patients aged 50 and over.
  • Exact FDA submission
  • Checked 2026-09-09
Workflow role
Post-acquisition DICOM CT validation and analysis in parallel with standard image storage and clinician availability, with automated vertebral labeling, segmentation, height and HU measurements, configurable flags, and clinician review.
  • Exact FDA submission
  • Checked 2026-09-09
Required input
DICOM CT scans of patients aged 50 and over undergoing any clinical indication, with at least four vertebrae in the T1-L4 portion for height-loss analysis and the T11-L4 portion for bone attenuation; FBP-reconstructed images only. Sagittal scans are intended, with axial scans as backup when sagittal scans are unavailable.
  • Exact FDA submission
  • Checked 2026-09-09
Output and clinician action
For each analyzed vertebra, a vertebral name, percentage height loss based on anterior/middle/posterior measurements, an indication when height loss exceeds a configurable threshold defaulting to >20%, mean trabecular-bone HU for T11-L4 with a configurable low-attenuation indication, and flags for significant height deviation from neighboring vertebrae.
  • Exact FDA submission
  • Checked 2026-09-09
Care setting
Clinical-center radiology infrastructure and parallel clinical imaging workflow; the FDA packet does not specify a facility type beyond clinical use.
  • Exact FDA submission
  • Checked 2026-09-09
Intended users
Clinicians, including radiologists and physicians in emergency medicine, specialty care, urgent care, and general practice.
  • Exact FDA submission
  • Checked 2026-09-09
Limitations
Use is limited to patients aged 50 and over, FBP-reconstructed CT, and the required vertebral coverage. Height-loss and bone-attenuation display thresholds are configurable from predefined lists. Axial analysis is a backup when sagittal data are unavailable, and the device is not intended as a standalone diagnostic tool.
  • Exact FDA submission
  • Checked 2026-09-09
Evidence summary
FDA stand-alone retrospective testing used 150 anonymized CT cases containing 1,425 vertebrae from two healthcare institutions with multiple US and OUS clinical sites; ground truth was determined by three US board-certified radiologists. Overall vertebral-naming agreement was 91.49% (95% CI [89.91%, 92.89%]); height-loss 95% limits of agreement were [-7.98, 7.36], with 91.86% of differences within the ground-truth readers' limits; agreement for classifying height loss above or below 20% was 91.28%; bone-attenuation 95% limits of agreement were [-20.83, 18.29], with 96.06% of differences within ground-truth readers' limits. These are agreement and limits-of-agreement endpoints, not sensitivity or specificity.
  • Exact FDA submission
  • Checked 2026-09-09

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA stand-alone retrospective testing used 150 anonymized CT cases containing 1,425 vertebrae from two healthcare institutions with multiple US and OUS clinical sites; ground truth was determined by three US board-certified radiologists. Overall vertebral-naming agreement was 91.49% (95% CI [89.91%, 92.89%]); height-loss 95% limits of agreement were [-7.98, 7.36], with 91.86% of differences within the ground-truth readers' limits; agreement for classifying height loss above or below 20% was 91.28%; bone-attenuation 95% limits of agreement were [-20.83, 18.29], with 96.06% of differences within ground-truth readers' limits. These are agreement and limits-of-agreement endpoints, not sensitivity or specificity.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

HealthOST regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K213944
  • Samplen=150
  • IndependenceIndependence not established

K213944

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K213944. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM CT scans of patients aged 50 and over undergoing any clinical indication, with at least four vertebrae in the T1-L4 portion for height-loss analysis and the T11-L4 portion for bone attenuation; FBP-reconstructed images only. Sagittal scans are intended, with axial scans as backup when sagittal scans are unavailable.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-09 · FDA K213944: HealthOST

  2. Routing

    Source context, not route validation: The packet describes DICOM-compliant clinical-center infrastructure, IMA integration for study results, and error codes for validation or analysis failure; it does not establish a specific PACS, RIS, EHR, interface version, or hosting model.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-09 · FDA K213944: HealthOST

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 ·

  4. Returned objects

    Source context, not route validation: For each analyzed vertebra, a vertebral name, percentage height loss based on anterior/middle/posterior measurements, an indication when height loss exceeds a configurable threshold defaulting to >20%, mean trabecular-bone HU for T11-L4 with a configurable low-attenuation indication, and flags for significant height deviation from neighboring vertebrae.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-09 · FDA K213944: HealthOST

  5. Viewer/worklist/report

    Unresolved route: For each analyzed vertebra, a vertebral name, percentage height loss based on anterior/middle/posterior measurements, an indication when height loss exceeds a configurable threshold defaulting to >20%, mean trabecular-bone HU for T11-L4 with a configurable low-attenuation indication, and flags for significant height deviation from neighboring vertebrae.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-09 · FDA K213944: HealthOST

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
The packet describes DICOM-compliant clinical-center infrastructure, IMA integration for study results, and error codes for validation or analysis failure; it does not establish a specific PACS, RIS, EHR, interface version, or hosting model.
  • Exact FDA submission
  • Checked 2026-09-09

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

Supported acquisition environment

Scanner manufacturers: All

exact submission · checked 2026-09-01

Confirm currently supported software versions, protocols, and site-specific acquisition configurations.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for HealthOST; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K213944
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Anatomy
Spine, including T1-L4 vertebrae and T11-L4 trabecular bone regions
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2022-04-22
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
24Fields reviewed
9Source classes checked
2Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 2 PubMed and 0 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 2 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K213944 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Deployment: Not publicly available - checked 2026-11-14 - Exact FDA submission

    The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-09 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-09 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K213944: HealthOST

    U.S. Food and Drug Administration - Published 2022-04-22 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. HealthOST model card (K213944)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K213944

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

Research history

  1. K213944 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260322

Acorn 3D Software (AC-SEG-4009); Acorn 3DP Model (AC-101-XX)

Mighty Oak Medical

Authorized purpose: Acorn 3D Software and Acorn 3DP Model process CT, synthetic CT, and CT angiography for segmentation, visualization, measurement, treatment planning, and three-dimensional printing, including adult and pediatric spine trajectory planning.

Modality
CT/CTA
Anatomy
Spine; craniomaxillofacial; musculoskeletal anatomy; and patient-specific printed models
Decision
2026-06-11
FDA-cleared K252029

AI-CVD

HeartLung Corporation

Authorized purpose: AI-CVD provides automated quantitative CT-derived anatomical and density measurements for clinician review, including calcium scores, cardiac and vascular measurements, lung and liver density, bone mineral density, and muscle/fat composition; it is opportunistic decision support, not diagnostic interpretation or risk prediction.

Modality
CT/CTA
Anatomy
Chest, abdomen, heart, lungs, liver, aorta, pulmonary artery, bone, muscle, and fat
Decision
2025-12-19
FDA-cleared K252103

Acorn 3D Software (AC-SEG-4009); Acorn 3DP Model (AC-101-XX)

Mighty Oak Medical

Authorized purpose: Acorn 3D Software provides modular image processing, visualization, segmentation, measurement, treatment planning, and three-dimensional-printing support; Acorn Trajectory Automation plans pedicle-screw trajectories in adult and pediatric thoracic and lumbar spine cases.

Modality
CT/CTA
Anatomy
Thoracic and lumbar spine, musculoskeletal, craniomaxillofacial, and vascular anatomy
Decision
2025-12-02

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history